CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich

Published: Apr 09, 2018

MONMOUTH JUNCTION, N.J., April 9, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD and Chief Financial Officer, Ms. Kathy Bloch will meet with European investors this week at the H.C. Wainwright Annual Global Life Sciences Conference on April 9-10, 2018 in Monte Carlo, Monaco and in separate meetings in Frankfurt, Germany, as well as Zurich and Geneva, Switzerland on April 11-13, 2018.

https://mma.prnewswire.com/media/664088/CYTOSORBENTS_Logo.jpg

Dr. Chan will also present at the H.C. Wainwright conference and provide an overview of the company later today.

H.C. Wainwright Annual Global Life Sciences Conference

    Where:   Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco

    When:    Monday, April 9, 2018 from 3:00-3:25 PM CEST

    Room:    Salon Atlantic - W, 2nd floor

    Webcast: http://wsw.com/webcast/hcw2/ctso/

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 45 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents recently initiated its pivotal REFRESH 2 trial - a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury. CytoSorb® has been used in more than 35,000 human treatments to date.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly $22 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique patented blood purification technology including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Back to news